Crescent Grove Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-19,344
| Closed | -$493K | – | 309 |
|
|
2025
Q3 | $493K | Buy |
+19,344
| New | +$477K | 0.05% | 171 |
|
|
2024
Q4 | – | Sell |
-7,719
| Closed | -$223K | – | 290 |
|
|
2024
Q3 | $223K | Sell |
7,719
-1,141
| -13% | -$33.3K | 0.02% | 256 |
|
|
2024
Q2 | $248K | Sell |
8,860
-7,160
| -45% | -$197K | 0.03% | 240 |
|
|
2024
Q1 | $445K | Sell |
16,020
-181
| -1% | -$5.02K | 0.05% | 196 |
|
|
2023
Q4 | $466K | Sell |
16,201
-569
| -3% | -$17.2K | 0.05% | 183 |
|
|
2023
Q3 | $556K | Sell |
16,770
-753
| -4% | -$26.6K | 0.07% | 161 |
|
|
2023
Q2 | $643K | Sell |
17,523
-353
| -2% | -$13.7K | 0.07% | 145 |
|
|
2023
Q1 | $729K | Buy |
17,876
+94
| +0.5% | +$4.06K | 0.08% | 134 |
|
|
2022
Q4 | $911K | Sell |
17,782
-935
| -5% | -$44.8K | 0.09% | 120 |
|
|
2022
Q3 | $819K | Sell |
18,717
-4,284
| -19% | -$208K | 0.09% | 114 |
|
|
2022
Q2 | $1.21M | Sell |
23,001
-1,462
| -6% | -$74.5K | 0.13% | 90 |
|
|
2022
Q1 | $1.27M | Buy |
24,463
+11,282
| +86% | +$585K | 0.12% | 93 |
|
|
2021
Q4 | $778K | Buy |
13,181
+635
| +5% | +$31.5K | 0.07% | 134 |
|
|
2021
Q3 | $540K | Sell |
12,546
-5,134
| -29% | -$227K | 0.06% | 148 |
|
|
2021
Q2 | $692K | Sell |
17,680
-625
| -3% | -$24.3K | 0.07% | 130 |
|
|
2021
Q1 | $663K | Buy |
18,305
+2,396
| +15% | +$85.1K | 0.08% | 112 |
|
|
2020
Q4 | $586K | Sell |
15,909
-649
| -4% | -$23.8K | 0.08% | 102 |
|
|
2020
Q3 | $577K | Sell |
16,558
-959
| -5% | -$33.6K | 0.12% | 90 |
|
|
2020
Q2 | $543K | Sell |
17,517
-827
| -5% | -$28.1K | 0.11% | 82 |
|
|
2020
Q1 | $568K | Buy |
18,344
+808
| +5% | +$27.5K | 0.13% | 69 |
|
|
2019
Q4 | $652K | Buy |
17,536
+3
| +0% | +$107 | 0.11% | 87 |
|
|
2019
Q3 | $598K | Sell |
17,533
-3,507
| -17% | -$128K | 0.11% | 81 |
|
|
2019
Q2 | $865K | Sell |
21,040
-573
| -3% | -$22.8K | 0.16% | 63 |
|
|
2019
Q1 | $871K | Sell |
21,613
-1,571
| -7% | -$62.9K | 0.18% | 60 |
|
|
2018
Q4 | $960K | Buy |
23,184
+242
| +1% | +$10K | 0.2% | 62 |
|
|
2018
Q3 | $959K | Buy |
22,942
+2
| +0% | +$77 | 0.21% | 59 |
|
|
2018
Q2 | $790K | Sell |
22,940
-4,730
| -17% | -$162K | 0.2% | 64 |
|
|
2018
Q1 | $932K | Sell |
27,670
-3,763
| -12% | -$129K | 0.23% | 56 |
|
|
2017
Q4 | $1.08M | Sell |
31,433
-1,783
| -5% | -$60.8K | 0.27% | 52 |
|
|
2017
Q3 | $1.13M | Sell |
33,216
-30
| -0.1% | -$964 | 0.29% | 50 |
|
|
2017
Q2 | $1.06M | Buy |
+33,246
| New | +$1.05M | 0.31% | 47 |
|
Other funds holding PFE
Crescent Grove Advisors's PFE Position: Q4 2025 in Review
Crescent Grove Advisors sold out of Pfizer (PFE) in Q4 2025, closing a stake of 19,344 shares — an estimated $493K sold.
Crescent Grove Advisors first reported a position in PFE in Q2 2017 and held it in 31 quarters. The position peaked at $1.27M in Q1 2022. 2,914 funds tracked by Wall St. Rank hold PFE as of Q4 2025.
- Crescent Grove Advisors reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
- Crescent Grove Advisors sold 19,344 Pfizer shares in Q4 2025, an estimated $493K.
- Crescent Grove Advisors first reported a position in Pfizer in Q2 2017 and held it in 31 quarters.
- Crescent Grove Advisors's Pfizer position peaked at $1.27M in Q1 2022.
- 2,914 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.
Based on Crescent Grove Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.